Gilead Sciences (GILD) Q2 2026 Earnings
Includes $(9.08) per share impact of acquired IPR&D expenses of $11.1 billion related to Arcellx, Tubulis, and Ouro Medicines acquisitions, net of Lakefront collaboration impact and related taxes, plus $1.07 per share IPR&D impairment related to previously acquired Immunomedics assets
How Did GILD Stock React to Q2 2026 Earnings?
S&P 500 over the same 30 days: +0.05%.
Did GILD Beat Earnings? Q2 2026 Results
Yes. Gilead Sciences reported Q2 2026 earnings of $-6.75 a share on Aug 4, 2026, beating the $-7.25 consensus estimate by 6.9%. Revenue was $7.8B against a $7.4B estimate.
Gilead Sciences delivered a stronger-than-expected second quarter, beating adjusted EPS and revenue estimates even as massive acquisition-related charges dominated the headline figures. The company posted adjusted diluted EPS of $-6.75, beating the consensus estimate of $-7.25 by 6.86%, marking the fifth consecutive quarter of adjusted EPS beats, while revenue of $7.80 billion topped expectations by 5.41% and grew 10.2% year over year. The results were heavily shaped by $11.18 billion in acquired in-process research and development expenses tied to the Arcellx, Tubulis, and Ouro Medicines acquisitions, along with a $1.75 billion IPR&D impairment on Immunomedics assets, driving a GAAP net loss of $10.50 billion. Beneath those charges, the underlying business showed genuine strength, with HIV product sales climbing 12% to $5.69 billion, led by Biktarvy's 7% growth to $3.77 billion and Yeztugo's rapid ramp to $232 million from just $15 million a year ago. Looking ahead, Gilead raised its full-year product sales guidance excluding Veklury to $29.80 billion to $30.10 billion and narrowed its non-GAAP diluted loss per share outlook to $-0.65 to $-0.30, reflecting improving base business momentum despite the acquisition-driven distortions.
- HIV product sales grew 12% driven by higher average realized price and demand
- Biktarvy growth of 7% on higher average realized price, favorable inventory dynamics and higher demand
- Descovy surged 48% on higher average realized price and PrEP demand expansion
- Yeztugo ramped to $232 million from $15 million a year ago
- Trodelvy grew 26% on higher demand and new first-line mTNBC indication
- Livdelzi contributed to Liver Disease portfolio growth of 10%
- Royalty, contract and other revenues increased to $176 million from $27 million
“Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi. HIV sales grew 12%, reflecting continued strength in treatment and the rapid expansion of our PrEP business, supporting an increase in our base business revenue expectations for 2026.”
Gilead Sciences CEO, on the earnings call
What Is Gilead Sciences's Outlook?
Gilead raised its full-year 2026 product sales guidance to $30.1–$30.4 billion (from $30.0–$30.4 billion), with product sales excluding Veklury raised to $29.8–$30.1 billion (from $29.4–$29.8 billion). Veklury guidance was reduced to approximately $300 million (from approximately $600 million). Full-year GAAP diluted loss per share is now expected at $(3.75) to $(3.40) (previously $(3.25) to $(2.85)), and non-GAAP diluted loss per share is expected at $(0.65) to $(0.30) (previously $(1.05) to $(0.65)). Both GAAP and non-GAAP EPS guidance include approximately $(9.08) per share from acquired IPR&D charges of $11.1 billion related to the Arcellx, Tubulis and Ouro Medicines transactions. The company expects two potential launches in the second half of 2026 in oncology and HIV.
GILD YoY Financials
| Metric | Q2 2026 | Q2 2025 | Year over year |
|---|---|---|---|
| Revenue | $7.8B | $7.1B | +10.2% |
| Gross Profit | $6.0B | $5.6B | +8.4% |
GILD Revenue by Segment
GILD Revenue by Geography
When Does Gilead Sciences Report Next?
Figures from SEC filings and company reports. Not investment advice.